Minneapolis Heart Institute Foundation

What it reported doing in 2024

2024 mhif research accomplishmentsi.mhif reached an important research milestone with u.s. Fda approval of the triclip (abbott), a non-surgical, transcatheter edge-to-edge repair system. Mhif was the top enroller - enrolling the first and largest number of patients of all 68 clinical sites participating in the triluminate pivotal trial in the u.s., canada and europe, led by paul sorajja, md, the roger l. And lynn c. Headrick family chair of the mhif valve science center and global principal investigator for the pivotal trial. The mhif imaging core lab, led by joao cavalcante, md, director of the mhif cardiovascular imaging research center, provided advanced cardiac imaging analysis for the pivotal trial. Ii.mhif initiated first enrollments in the precise procedural and pci plan (p4) research trial evaluating the potential for advanced cardiovascular imaging to enhance patient care. Patients receive ct imaging with state-of-the-art 3d modeling provided by the trial as part of pre-procedure planning to guide the pci used to open a blockage in the heart. The p4 research trial is a global, multicenter, randomized trial sponsored by coreaalst bv to compare novel coronary ct-guided pci and standard ivus-guided pci. The first u.s. Procedure for the p4 trial was performed by drs. Yader sandoval & emmanouil brilakis, in collaboration with drs. John lesser and joao cavalcante, all study investigators at mhif. Iii.mhif expertise brings leadership opportunities across research, including first-in-world opportunities with new technologies: mhif principal investigator dr. John zakaib was among the first to enroll patients and remains the top enroller in the leadr clinical study evaluating novel conduction system pacing with investigational omniasecure defibrillation lead (medtronic). Mhif team with drs. Paul sorajja, vinayak bapat and nadira hamid enrolled the first patient in the u.s. Vista early feasibility study for a new transcatheter tricuspid valve technology (vdyne). Mhif principal investigator dr. Jay traverse enrolled the first patient in the super-saturated oxygen comprehensive observational registry to provide efficacy evidence for sso2 therapy (zoll) to reduce heart failure and mortality after left anterior descending st-elevation myocardial infarction (lad stemi) heart attacks. Iv.mhif was recognized as one of the 2024 crf scientific excellence top 10 (set-10) for outstanding research and groundbreaking contributions to interventional cardiovascular medicine, presented at tct 2024. This prestigious recognition reflects the relentless dedication, innovation, and hard work of mhif physicians and scientists, whose research exemplifies the significant advancements they are driving in the field of cardiovascular medicine.v.2024 stats:- 350+ new patients enrolled in research; 220+ active studies with 2200+ patients at any given time- 3,000+ visits with patients who have hope and options through research - 270 publications in leading, peer-reviewed journals (a complete listing of mhif publications in 2024 is available at mplsheart.org/2024publications - 90+ posters and abstracts accepted to national and international conferences - 245 podium presentations and invited talks - 15 media presentations - 90,000+ downloads from physicians around the world for the suite of mhif digital applications available sharing expertise and clinical insights in heart valve and coronary artery disease - 8 mhif international scholars contributed to advancing research; these scholars are practicing medical doctors from around the world who come to mhif to participate in research in partnership with leading mhif research physicians - 11,000+ hours of professional and community education each year reaching 4,000+ attendees - 5,500+ members of the community celebrated the impact of lifesaving research at mhif's heart360 concert for world-class heart research with brad paisley at the armory in minneapolis.

Financial Efficiency

• Mission deployment rate: 57.9%; rating input score 58
• Program expense ratio: 67.2%; rating input score 67
• Fundraising efficiency: $6.6 raised per $1 spent on fundraising; rating input score 27; 27th percentile among comparable filings

Transparency & Controls

• Consistency checks: 94.7%; rating input score 95; 24th percentile among comparable filings
• Pay-setting controls: 4 of 6 controls in place; rating input score 67
  • Compensation committee: Pass
  • Independent consultant: Missing
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: 99.3%; rating input score 99; 33rd percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 66th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 17.7%; rating input score 80; 80th percentile among comparable filings
• Total-asset coverage ratio: 3.83; rating input score 80; 80th percentile among comparable filings
• Liabilities to assets ratio: 0.14; rating input score 67; 67th percentile among comparable filings
• Officer compensation ratio: 14.8%; rating input score 8; 8th percentile among comparable filings

Growth

• Program expense growth: 5.5% per year; rating input score 100; 46th percentile among comparable filings
• Revenue growth: 6.6% per year; rating input score 100; 56th percentile among comparable filings
• Asset growth: 9.7% per year; rating input score 100; 64th percentile among comparable filings